Advantage Alpha Capital Partners LP Decreases Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Advantage Alpha Capital Partners LP cut its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 32.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,196 shares of the biopharmaceutical company’s stock after selling 12,124 shares during the quarter. Advantage Alpha Capital Partners LP’s holdings in Catalyst Pharmaceuticals were worth $501,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Larson Financial Group LLC boosted its stake in shares of Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 2,994 shares during the period. Cerity Partners LLC grew its stake in shares of Catalyst Pharmaceuticals by 31.3% during the third quarter. Cerity Partners LLC now owns 28,733 shares of the biopharmaceutical company’s stock valued at $571,000 after buying an additional 6,847 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 4.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company’s stock worth $23,215,000 after buying an additional 50,804 shares during the period. Intech Investment Management LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter worth approximately $644,000. Finally, Advisors Asset Management Inc. boosted its holdings in Catalyst Pharmaceuticals by 6.9% during the 3rd quarter. Advisors Asset Management Inc. now owns 177,333 shares of the biopharmaceutical company’s stock valued at $3,525,000 after acquiring an additional 11,484 shares during the period. 79.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Truist Financial lifted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Stephens started coverage on shares of Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 price target for the company. Finally, Citigroup increased their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Stock Up 3.5 %

Catalyst Pharmaceuticals stock opened at $21.93 on Wednesday. The firm has a market cap of $2.62 billion, a P/E ratio of 18.58, a P/E/G ratio of 3.31 and a beta of 0.75. The business has a fifty day moving average of $21.14 and a two-hundred day moving average of $18.62. Catalyst Pharmaceuticals, Inc. has a twelve month low of $13.00 and a twelve month high of $24.27.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.